Corrigendum: Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies

• Satoshi Motoya,
• Mamoru Watanabe,
• Hyo Jong Kim,
• Young Ho Kim,
• Dong Soo Han,
• Hirotoshi Yuasa,
• Junichi Tabira,
• Naoki Isogawa,
• Shoko Arai,
• Isao Kawaguchi,
• Toshifumi Hibi

Affiliations

Satoshi Motoya

IBD Center, Sapporo Kosei General Hospital, Sapporo, .Japan

Mamoru Watanabe

Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, .Japan

Hyo Jong Kim

Division of Gastroenterology, Department of Internal Medicine, Kyung Hee University School of Medicine, Seoul, .Korea

Young Ho Kim

Division of Gastroenterology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, .Korea

Dong Soo Han

Department of Internal Medicine, Hanyang University Guri Hospital, Guri, .Korea

Hirotoshi Yuasa

Inflammation & Immunology, Pfizer Japan Inc, Tokyo, .Japan

Junichi Tabira

Inflammation & Immunology, Pfizer Japan Inc, Tokyo, .Japan

Naoki Isogawa

Inflammation & Immunology, Pfizer Japan Inc, Tokyo, .Japan

Shoko Arai

Inflammation & Immunology, Pfizer Japan Inc, Tokyo, .Japan

Isao Kawaguchi

Inflammation & Immunology, Pfizer Japan Inc, Tokyo, .Japan

Toshifumi Hibi

Center for Advanced IBD Research and Treatment, Kitasato University, Tokyo, .Japan